Free Newsletter
Imaging integration boosts trial data system
An imaging capability integrated with its clinical software suite has earned trial technology provider PharmaVigilant a contract with TissueGene. The regenerative-medicine maker is running a Phase II study for a drug candidate to treat a degenerative joint disease of the knee.
MRIs, typically too large to be opened in an EDC system, provide a method of determining biomarkers for use in drug development, says the software company. Integration of MRIs with trial data systems reduces the number of steps that researchers take to access and review the images. It lets sponsors manage our trial participants' MRIs "through one integrated solution with a single login, rather than relying on a separate organization to provide these capabilities," says Kwan Hee Lee, CEO at TissueGene, in an announcement.
PharmaVigilant's system is called I-Vault. Its subsystems correspond with the company's view of two submission components for clinical trials: I-Vault eTMF (electronic trial master file) is a repository for site- and patient-related data. The I-Vault rSDV (remote source document verification) system provides data monitoring independent of site visits.
- here's the announcement
Related Articles:
Imaging biomarkers to aid arthritis research
Imaging studies target cardiac disease, cancer
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
